Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2026 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

LAB
The Conversation (0)
Brixton Metals Drills 6,199 g/t Silver over 1.00 m including 0.50 m of 12,386 g/t Silver in Hole 432 at its Langis Project in Ontario

Brixton Metals Drills 6,199 g/t Silver over 1.00 m including 0.50 m of 12,386 g/t Silver in Hole 432 at its Langis Project in Ontario

Hole 399: 4.60 m of 503 g/t Silver Hole 408: 7.00 m of 290 g/t Silver including 2.00 m of 958 g/t Silver Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the "Company" or "Brixton") is pleased to report additional silver results from 33 holes at its wholly owned Langis Silver Project,... Keep Reading...
Cascadia Drills 82.69 m of 1.12% Cu and 0.64 g/t Au  at the Carmacks Project, Yukon

Cascadia Drills 82.69 m of 1.12% Cu and 0.64 g/t Au at the Carmacks Project, Yukon

Cascadia Minerals Ltd. ("Cascadia") (TSX-V: CAM) (OTCQB: CAMNF) is pleased to announce the results of five additional drill holes from its fully-funded 2026 exploration program at the road-accessible Carmacks copper-gold project in central Yukon. These results continue to expand mineralization... Keep Reading...
Lahontan Drills 10.7m Grading 1.81 g/t Au and 64.8 g/t Ag, Completes Santa Fe Mine Stockpile Drill Program

Lahontan Drills 10.7m Grading 1.81 g/t Au and 64.8 g/t Ag, Completes Santa Fe Mine Stockpile Drill Program

Lahontan Gold Corp. (TSXV:LG,OTC:LGCXF, OTCQB:LGCXF, FSE:Y2F) (the "Company" or "Lahontan") is pleased to announce additional results from its 2026 Sonic core drilling program at the Santa Fe Mine Project. The Sonic drilling campaign is evaluating historic heap leach pads and stockpiles to... Keep Reading...
Gold Runner Exploration Samples up to 25,306 Grams per Ton Silver with 11.22 Grams per Ton Gold for a Gold Equivalent of 12.7 Ounces per Ton in New 350 Meter Gold Stack Trend on the 100% Controlled Golden Girl Property, Golden Triangle, B.C.

Gold Runner Exploration Samples up to 25,306 Grams per Ton Silver with 11.22 Grams per Ton Gold for a Gold Equivalent of 12.7 Ounces per Ton in New 350 Meter Gold Stack Trend on the 100% Controlled Golden Girl Property, Golden Triangle, B.C.

Gold Runner Exploration Inc. (CSE: GRUN) (FSE: CE70) ("Gold Runner" or the "Company") is pleased to announce initial results for samples assayed up to 25,306 gt Ag (grams per ton Silver) with 11.2 gt Au (grams per ton Gold), or 12.7 ounces per ton Gold Equivalent, from the newly discovered 350... Keep Reading...
Shareholder Update

Shareholder Update

BLACK DRAGON RESOURCE COMPANY PROVIDES CORPORATE UPDATE; TEXAS FRAC SAND ACQUISITION REMAINS ON TARGET, FULL LONQUIST REPORT ATTACHED, AND OPEN-MARKET SHARE BUYBACK TO BEGIN AUGUST 31 DALLAS, TX / ACCESS Newswire / August 27, 2026 / Black Dragon Resource Companies, Inc. (OTC PINK:BDGR) ("Black... Keep Reading...
BriaCell Therapeutics (TSX:BCT)

BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation

Clinical-stage immuno-oncology company BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) has achieved a “key genetic engineering milestone” with ‘Melanoma’, its personalized whole-cell melanoma immunotherapy vaccine candidate.The achievement allows the vaccine’s program to proceed towards clinical... Keep Reading...
Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received... Keep Reading...
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

(TheNewswire) Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the... Keep Reading...
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0... Keep Reading...
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2026

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind,... Keep Reading...
Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Enters a Material Transfer Agreement With PegBio

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's... Keep Reading...

Interactive Chart

Latest Press Releases

Related News